Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)
- 11 August 2016
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 35 (5) , 827-838
Abstract
Purpose This large dose-ranging study explored the benefits of different combinations of mirabegron and solifenacin on health-related quality of life (HRQoL), based on patient-reported outcomes (PROs), and patients (‘responders’) achieving clinically meaningful improvements in efficacy and HRQoL. Methods SYMPHONY (NCT01340027) was a Phase II, placebo- and monotherapy-controlled, dose-ranging, 12-week trial. Adult patients with overactive bladder (OAB) for ≥3 months were randomized to 1 of 12 groups: 6 combination (solifenacin 2.5/5/10 mg + mirabegron 25/50 mg), 5 monotherapy (solifenacin 2.5/5/10 mg, or mirabegron 25/50 mg), or placebo. Change from baseline to end of treatment was assessed, versus placebo and solifenacin 5 mg in: PROs (OAB-q [Symptom Bother/total HRQoL] and Patient Perception of Bladder Condition score), and responders achieving minimally important differences (MIDs) in PROs and predetermined clinically meaningful improvements in efficacy (e.g. p = 0.023]) and 5 + 50 mg (OR 1.91 [95 % CI 1.14, 3.21; p = 0.015]) versus solifenacin 5 mg. Conclusion Combining mirabegron 25/50 mg and solifenacin 5/10 mg improves objective and subjective efficacy outcomes compared with placebo or solifenacin 5 mg.Keywords
Funding Information
- Astellas Pharma Inc
This publication has 30 references indexed in Scilit:
- Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013Neurourology and Urodynamics, 2014
- Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literatureInternational Journal Of Clinical Practice, 2011
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placeboHealth and Quality of Life Outcomes, 2009
- Disease Burden of Overactive BladderPharmacoEconomics, 2007
- Redefining response in overactive bladder syndromeBJU International, 2006
- Determining the Importance of Change in the Overactive Bladder QuestionnaireJournal of Urology, 2006
- Solifenacin Is Effective for the Treatment of OAB Dry Patients: A Pooled AnalysisEuropean Urology, 2005
- Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-qQuality of Life Research, 2002
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002